Moderna launched RSV vaccine mResvia in 2024 as the third ... We think the firm's rapid development timeline during the pandemic shows strong execution with its clinical, manufacturing, and ...

In GSK’s suit against Pfizer, the British pharma was seeking monetary damages or royalties and potentially a permanent injunction on the commercialization of Pfizer’s RSV vaccine in the U.S.

The ACIP has now recommended the use of GSK’s RSV vaccine, Arexvy, and PFE’s RSV vaccine, Abrysvo, in adults aged 50-59 who are at high risk of severe RSV disease. Individuals with underlying ...

has voted to recommend the use of respiratory syncytial virus (RSV) vaccines, including GSK's adjuvanted Arexvy, for use in the adult population between the ages of 50 and 59 who are at higher ...

GSK (GSK) said it is “pleased” that the Advisory Committee on Immunization Practices voted in favor of recommending the use of RSV vaccines including GSK’s AREXVY in adults aged 50-59 who ...

GSK) are expected to reap benefits as an advisory committee of the CDC on Wednesday voted to expand the use of vaccines against the respiratory syncytial virus (RSV) for a broader population in ...

The reversal from the Advisory Committee on Immunization Practices (ACIP) is a potential boost for GSK and Pfizer. Both companies saw sales of their RSV vaccines for adults tumble last year after ...

In June 2024, ACIP postponed a vote on a recommendation for adults aged 50-59 at increased risk for RSV-LRTD until additional data becomes available. The recommendation also includes GSK plc’s ...

The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices voted to expand access to Pfizer’s respiratory syncytial virus vaccine Abrysvo for high-risk adults in ...

GSK said in the lawsuit that Pfizer began working on its RSV program around 2013, at least seven years after GSK began developing its shot. Pfizer denied the allegations and argued GSK's patents ...

GSK GSK and Pfizer PFE announced that the U.S. Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) has recommended the expanded use of their ...

which would represent a positive surprise for GSK, in our view.” While Moderna (MRNA) has an FDA-approved RSV vaccine, its messenger-RNA-based shot is only approved by the FDA for those aged 60 ...